Patient with histologically-proven ACLD

Slides:

Advertisements

Similar presentations

Machine learning methods for the analysis of heterogeneous, multi- source data Ilkka Huopaniemi Statistical machine learning and.

Advertisements

Hepatocirrhosis Liver cirrhosis.

Measurement of liver fibrosis Amar Dhillon Royal Free and University College Medical School.

Dietary Approach To C Kidney Disease

Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.

Update on Cholangiocarcinoma: What we have learned from the International Hepatobiliary Neoplasia Biorepository Roon Chaiteerakij, MD Mayo Clinic, Rochester,

V. Petrenkiene*, D. Petrauskas L. Kupcinskas, Lithuanian University of Health sciences Clinic of Gastroenterology Kaunas Utility of non-invasive markers.

Alpha 1 Antitrypsin Deficiency By Kyla Turnquist.

Weight Loss via Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis Gastroenterology 2015, /j.gastro

CIRRHOSISPathophysiology&Complications. What is Cirrhosis?

Periportal Fibrosis Without Cirrhosis Does Not Affect Outcomes Following Continuous Flow Ventricular Assist Device Implantation Jonathon E. Sargent, BS,

NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.

Evaluation of Liver Histology in Clinical Trials for Chronic Viral Hepatitis Zachary Goodman, M.D., Ph.D. Chief, Hepatic Pathology Armed Forces Institute.

ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.

FT in prognostic of HBV FibroTest: predictive value in HBV.

This research project has been co-financed by the European Union (European Regional Development Fund- ERDF) and Greek national funds through the Operational.

Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.

Hepatic Steatosis in patients with Autoimmune Hepatitis (AIH) – prevalence, progression and possible significance C. Salmon*1, B.Hoeroldt2, A. Dube3,

“Interpreting Your Test Results”

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Phase 3 Treatment-Naïve and Treatment-Experienced

Volume 46, Issue 3, Pages (March 2007)

Volume 32, Issue 2, Pages (February 2000)

Volume 41, Issue 6, Pages (December 2004)

Interactive Workshop.

Phase 3 Treatment-Naïve and Treatment-Experienced

HCV & liver transplantation

HBV Management in 2012… Where Are We Heading?

Volume 39, Issue 3, Pages (September 2003)

Additional file 2 Total HCC cases N=39

Alpha 1 Antitrypsin Deficiency

HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.

More Than Meets the Eye: Identifying Who Is at Risk for NASH

The New England Journal of Medicine (378;12) March 22, 2018

Incorrect Calculation and Inappropriate Interpretation: Accuracy of International Guidelines for Identifying Significant Fibrosis in e Antigen–Negative.

Predicting outcome after cardiac surgery in patients with cirrhosis: A comparison of Child-Pugh and MELD scores Amitabh Suman, David S. Barnes, Nizar.

Figure 2 A stage-based approach to the treatment of NAFLD

Rachel H. Westbrook, Andrew D. Yeoman, John G. O'Grady, Phil M

Evaluation of the Patient With HCV Infection

Non-invasive diagnosis of non-alcoholic fatty liver disease

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5 year open-label follow-up study Martin Gerbert,

Marcus-Alexander Wörns, Peter Robert Galle Journal of Hepatology

Volume 136, Issue 1, Pages (January 2009)

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Phase 3 Treatment-Naïve and Treatment-Experienced

Bleeding Complication With Liver Biopsy: Is It Predictable?

A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus Amit G. Singal, Michael.

Supersonic Shear Imaging and Transient Elastography With the XL Probe Accurately Detect Fibrosis in Overweight or Obese Patients With Chronic Liver Disease

Prevalence and Mechanisms of Malnutrition in Patients With Advanced Liver Disease, and Nutrition Management Strategies Kally Cheung, Samuel S. Lee, Maitreyi.

AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary.

European Association for the Study of the Liver Journal of Hepatology

Jean-Charles Nault, Peter R. Galle, Jens U. Marquardt

Diagnostic Value of Quantitative Hepatic Copper Determination in Patients With Wilson’s Disease Peter Ferenci, Petra Steindl-Munda, Wolfgang Vogel, Wolfgang.

Clinical Gastroenterology and Hepatology

From non-A, non-B hepatitis to hepatitis C virus cure

Trends in the management and burden of alcoholic liver disease

The Model for End-Stage Liver Disease (MELD) Predicts Early and Late Outcomes of Cardiovascular Operations in Patients With Liver Cirrhosis Naoto Morimoto,

Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B Eugene R. Schiff, Samuel S.

Management of cirrhosis due to chronic hepatitis C

Clinical Presentation, Outcome, and Response to Therapy Among Patients With Acute Exacerbation of Chronic Hepatitis C Evangelista Sagnelli, Mariantonietta.

Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis Linda Perkins, Mark Jeffries, Tushar Patel

Volume 60, Issue 1, Pages (January 2014)

Volume 142, Issue 6, Pages e4 (May 2012)

Assistant professor of Hepatology Alexandria University

Raymond D’Souza, Michael J

Volume 61, Issue 2, Pages (August 2014)

Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer Edoardo Giannini, Federica Botta,

Comparison of the area under the receiver operating curves (AUROCs) to predict 28-day (panel A) and 90-day (panel B) mortality of the chronic liver failure.

Reversion of disease manifestations after HCV eradication

Susana G. Rodrigues, MD-PhD student; Apr ‘17-Jul ’19, funded by the Stiftung für Leberkrankheiten Bern 1. Portal vein recanalisation with transjugular.

Presentation transcript:

Predictive factors of cirrhosis regression in patients with advanced chronic liver disease Patient with histologically-proven ACLD and successful elimination of causal factor (n=60) Clinical regression with a decrease of MELD ≥3 points or Child-Pugh ≥ 2 points and/or a decrease >1stage of fibrosis on Ishak systems or Laennec classification on liver biopsy after 24-60 months of therapy. CIRRHOSIS REGRESSION NO CIRRHOSIS REGRESSION on first and second liver samples. Genetic analysis of blood sample Metabolomic analysis of blood sample (before and 24 months after therapy) Transcriptomic analysis of liver tissue sample SNP genotyping NGS on liver samples Targeted analysis of amino acids Yuly Paulin Mendoza PhD student in Hepatology, UVCM, DBRM, Inselspital, University of Bern funding by Stiftung für Leberkrankheiten. Non-targeted analysis of lipids